Johns Hopkins President Ronald Peterson to retire at end of 2017

Ronald Peterson, president of Johns Hopkins Health System and executive vice president of Johns Hopkins Medicine, has announced he’ll retire at the end of 2017.

His 44-year tenure with the organization, which dates back to his administrative residency, was praised in an email to employees by Paul Rothman, MD, dean of the medical faculty and CEO of Johns Hopkins Medicine.

“In the life of an institution, there are leaders who leave such a deep and distinctive imprint that their influence spans well beyond the bounds of their career,” Rothman wrote. “Beyond any question, Ron has been instrumental to the success of this organization, and I have a profound appreciation for all of his contributions.”

Peterson’s leadership roles within the system over the years have included administrator of Johns Hopkins Children’s Center, executive director of Baltimore City Hospital and president of Johns Hopkins Bayview Medical Center. In 1996, he was named the 10th president of the Johns Hopkins Hospital, a role he held until July 2016.

According to the Baltimore Sun, his replacement will be current hospital president Redonda Miller. The Sun reported Peterson began making plans to retire when Miller was hired but wanted an “orderly transition” and a chance to mentor the new president.

After retiring, Peterson will serve for at least one year as special advisor to the dean of the medical faculty and CEO of Johns Hopkins Medicine.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.